Boehringer Ingelheim digs deep into the science and taking a precision approach to develop smart combinations to bring the greatest benefit to patients.
Maintenance treatment of patients with COPD (including chronic bronchitis and emphysema), maintenance treatment of associated dyspnoea and for prevention of exacerbations.
Our Code of Conduct sets the ethical standards that guides all our business activities. It´s about all of us. Each individual plays a vital role in bringing the Code of Conduct to live.
Boehringer Ingelheim’s research approach in stromal biology may lead to new medicines that will change the face of cancer and give new hope to patients
Boehringer Ingelheim produces lay summaries of clinical trials, making complex information and data from clinical studies understandable for patients and carers.
Boehringer Ingelheim Saudi Arabia Hosts Virtual Summit on the Latest Updates in Diabetes, Cardio
Boehringer Ingelheim Saudi Arabia Hosts Virtual Summit on the Latest Updates in Diabetes, Cardio-Metabolism, Respiratory Diseases and Stroke Management
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
Topline data from FIBRONEER™-IPF show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in Forced Vital Capacity [mL] at week 52 versus placebo.